Innoviva, Inc. (INVA) compared with its closest peers (ARDX, ESPR, ARQT, NATR, AVIR): P/E 4.0 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Ardelyx, Esperion Therapeutics, Arcutis Biotherapeutics, Nature's Sunshine Products, Atea Pharmaceuticals, MannKind, Mirum Pharmaceuticals, CorMedix, Organogenesis and Ironwood Pharmaceuticals share Innoviva's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Ardelyx, Inc. (ARDX) | $968.09M | -22.4 |
| Esperion Therapeutics, Inc. (ESPR) | $821.21M | -33.7 |
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.15B | -223.4 |
| Nature's Sunshine Products, Inc. (NATR) | $252.32M | 13.2 |
| Atea Pharmaceuticals, Inc. (AVIR) | $434.71M | -1.8 |
| MannKind Corporation (MNKD) | $1.33B | 283.0 |
| Mirum Pharmaceuticals, Inc. (MIRM) | $5.87B | -168.0 |
| CorMedix Inc. (CRMD) | $638.36M | 3.4 |
| Organogenesis Holdings Inc. (ORGO) | $231.61M | 34.5 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Stock P/E | 4.0 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -81.5% |
| vs Industry | -76.6% |
INVA overview · INVA earnings · INVA financials · INVA KPIs · INVA documents · INVA ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.